It has invested $2 billion and spent $200 million on its R&D centre in Bengaluru, the largest such centre outside China where some core technologies are under development.
The procurement and distribution will be centralised though the government is yet to take a call on the initial number of doses that will be procured.
Growth has been under pressure since the lockdowns related to Covid-19 started and fresh prescription generations slowed.
Two of Apple Inc's global vendors -- Wistron and Foxconn (through Han Hoi), which already manufacture Apple phones in India -- and a third entity, Pegatron, which will be setting up a new plant, have applied to the government to be eligible under the PLI scheme for large-scale electronics manufacturers.
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its candidate.
Serum Institute is investing $200 million to create capacities for the COVID-19 vaccine. Sohini Das profiles its 39-year-old CEO.
Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate Covid-19 disease.
Under these rules, telecom gear makers have to share their source codes and get their equipment tested by third-party labs accredited to the government.
India's telecom sector has been through dizzying peaks, troughs, policy U-turns, court battles, brutal competition, and daily controversies. India could go back to a private sector duopoly with just Reliance Jio and Bharti Airtel surviving the mayhem. The third player, Vodafone Idea, could be history.
Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic.
While the process of extracting plasma itself is simple, doctors say that it is the screening of donors, testing and filling up of numerous forms that takes time.
Pune's Serum Institute of India, the world's largest vaccine maker by volume, is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222 with CEO Adar Poonawalla stating he would start manufacturing at personal risk.
Companies say that unlike in the US and other countries, in India the high cost of rentals and lower ticket price makes it unviable to run an operation without half the seats available for sale.
Chingari, Roposo, Khabri and Trell are seeing huge traction as people are looking at options to earn incentives from home. Music streaming app Gaana, which is strongly placed in the market with 150 million users, recently opened up its short video platform for subscribers.
The two cities finally got their act together by ramping up the testing capacity and implementing stricter quarantine norms.
Reliance is leveraging the technological change of building a virtualised 5G network which would see the current hardware-dependent networks shift to software-centric platforms.
Apart from digital advertising revenue, both companies want to reach out to the 'next billion' Indian customers. After all, around half of the 1.3 billion population is still not on the net and this represents a challenge as well as an opportunity.
The Drug Controller General of India has sent a letter to the Glenmark seeking clarifications on pricing as well as claims of therapeutic efficacy. While Glenmark has claimed this drug is effective in comorbid conditions like diabetes, hypertension, according to protocol summary (of clinical trials) the trial was not designed to access the Fabiflu in comorbid conditions.
According to software company Mavernir, the new virtualised networks would lead to a saving of 40 per cent in capex and 34 per cent in terms of lower operations cost for operators.
Beside RIL's Jio Switch and Jio Browser, smaller Indian app companies who have been overwhelmed by TikTok are again seeing a big rush - even though till the second week of June they might not have been even listed in the top 100 apps in the country.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances